Pfizer has won a $10 billion deal to acquire the fast-rising obesity drug developer Metsera, ending a fierce bidding war with Danish rival Novo Nordisk.Metsera accepted a sweetened offer from Pfizer late Friday, citing U.S. antitrust risks in Novo’s bid that it had previously called superior, according to Reuters. The Danish obesity-drug giant said Saturday it would exit the race.The win gives Pfizer a foothold in the lucrative obesity-drug market, even though Metsera’s treatments remain years away from approval. The loss marked a setback for Novo as it tries to claw back ground from U.S. riva...

3 hours ago

On HALO